

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10560209	
	Filing Date		2006-10-16	
	First Named Inventor	Waksal, Samuel		
	Art Unit	1642		
	Examiner Name	Aeder, Sean E.		
Attorney Docket Number		13821/48902		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560209
Filing Date	2006-10-16
First Named Inventor	Waksal, Samuel
Art Unit	1642
Examiner Name	Aeder, Sean E.
Attorney Docket Number	13821/48902

1	NORMANNO N ET AL: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth, Annals of Oncology, Kluwer, Dordrecht, NL, vol. 13, no 1 January 2002 (2002-01), pages 65-72, XP02302015 ISSN:0923-7534	<input type="checkbox"/>
2	SCHILLER JOAH H: New directions for ZD18329 in the treatment of solid tumors, Seminars in Oncology FEB 2003, vol. 30, no. 1 Suppl 1, February 2003 (2003-02), pages 49-55 XP09052600 ISSN:0093-7754	<input type="checkbox"/>
3	COHEN, R.B., "Epidermal Growth Factor Receptor as a Thearpeutic Target in Colorectal Cancer," Clin. Colorectal Cancer 2003, Feb.; 2(4):246-51	<input type="checkbox"/>
4	KUROKAWA H, et al., ErbB (HER) Receptors Can Abrogate Antiestrogen Action in Human Breast Cancer by Multiple Signaling Mechanisms," Clin. Cancer Res. 2003 Jan; 9(1 PT 2): 511S-5S, PMID: 12538508 abstract)	<input type="checkbox"/>
5	English translation of Russian Federation Office Action referring to document D3	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Sean Aeder/ (07/23/2008)	Date Considered	
--------------------	---------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.